Summary
Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or β-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study. Significant reduction in mean blood pressure was achieved. Supine and erect systolic and diastolic blood pressure fell by 44/25 mmHg and 37/24 mmHg respectively over the study period of 12 weeks. Side-effects such as dizziness, headache, facial flushing and mild oedema were experienced by 10 patients during the study, all of which were mild and transient and did not require withdrawal from pinacidil therapy. Pinacidil is an effective and well tolerated agent in the treatment of essential hypertension.
References
Arrigoni-Martelli E, Kaergaard-Nielsen C, Olsen UB, Petersen HJ (1980) N″cyano-N-4-pyridyl-N′-1,2, 2-trimethylpropylguanidine monohydrate (P 1134): a new, potent vasodilator. Experientia 36: 445–447
Carlsen JE, Kardel T, Hilden T, Tangø M, Trap-Jensen J (1981) Immediate central and peripheral haemodynamic effects of a new vasodilating agent, P 1134, in hypertensive man. Clin Physiol 1: 375–384
Guyton AC, Coleman TG, Cowley AW, Scheel KW Jr, Manning RD Jr, Norman RA Jr (1972) Arterial pressure regulation. Overriding dominance of the kidneys in longterm regulation and in hypertension. Am J Med 52: 584–594
Kardel T, Hilden T, Carlsen J, Trap-Jensen J (1981) P 1134, a new vasodilating agent. Acute effect on blood pressure and pharmacokinetics in hypertensive patients. J Cardiovasc Pharmacol 3: 1002–1007
Koch-Weser J (1976) Hydralazine. N Engl J Med 295: 320–323
Petersen HJ, Haergaard Nielsen Chr, Arrigoni-Martelli E (1978) Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines. J Med Chem 21: 773–781
Ramsey LE (1980) Diuretic and beta-blocker in hypertension — then what? J Roy Coll Phys Lond 14: 249–253
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
D'Arcy, V., Laher, M., McCoy, D. et al. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. Eur J Clin Pharmacol 28, 347–349 (1985). https://doi.org/10.1007/BF00543335
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543335